Improving the diagnosis and treatment level of rheumatic and autoimmune diseases in children

MA Ming-sheng; ZHOU Yu; SONG Hong-mei

doi:10.19538/j.ek2025090603

Abstract：Remarkable progress has been made in diagnosis and treatment level of rheumatic and autoimmune diseases in children in recent years.On the diagnostic front,the advent of biomarker-driven disease stratification has revolutionized patient management by enabling early identification of high-risk individuals and facilitating personalized treatment plans.The expanding clinical application of genetic sequencing has particularly enhanced our comprehension of monogenic lupus and other prevalent childhood autoimmune disorders.Concurrently,diagnostic classification systems are undergoing continuous refinement to keep pace with the precision medicine paradigm shift.Therapeutic advancements have been equally transformative.Early,standardized intervention has emerged as a critical factor in preventing irreversible organ damage and optimizing long-term prognosis.Modern treatment strategies now feature increasingly targeted immunosuppressive regimens,while the accelerated development of biologic agents has substantially expanded the therapeutic arsenal for pediatric rheumatic diseases.Particularly promising are novel cellular therapies that show great potential in this evolving landscape.These collective developments underscore the growing importance of molecular-guided stratified diagnosis and tailored therapeutic interventions as fundamental components in elevating the standard of care for pediatric rheumatic and autoimmune disorders.